Cover ImageSALE
市場調查報告書

痛風治療藥的全球市場:2016年∼2020年

Global Gout Therapeutics Market 2016-2020

出版商 TechNavio (Infiniti Research Ltd.) 商品編碼 382929
出版日期 內容資訊 英文 59 Pages
訂單完成後即時交付
價格
Back to Top
痛風治療藥的全球市場:2016年∼2020年 Global Gout Therapeutics Market 2016-2020
出版日期: 2016年10月25日 內容資訊: 英文 59 Pages
簡介

全球痛風治療藥市場,預計2016年∼2020年以17.16%的年複合成長率 (CAGR) 成長。

本報告提供全球痛風治療藥市場相關調查分析,市場規模與成長率,市場趨勢,市場的推動要素與課題,市場機會驗證,主要供應商等相關的系統性資訊。

第1章 摘要整理

第2章 調查範圍

  • 市場概要
  • 主要供應商產品

第3章 市場調查手法

  • 調查手法
  • 經濟指標

第4章 簡介

第5章 痛風:疾病概要

第6章 產品研發線

第7章 市場形勢

  • 市場概要
  • 波特的五力分析

第8章 主要購買標準

第9章 痛風治療藥的全球市場:各藥物分類

  • 非類固醇消炎劑 (NSIDs)
  • 皮質類固醇
  • 秋水仙鹼
  • 尿酸降落藥

第10章 痛風治療藥的全球市場:疾病的各類型

第11章 痛風治療藥的全球市場:各地區

  • 南北美洲
  • 歐洲、中東、非洲
  • 亞太地區
  • 市場概要

第12章 痛風治療藥的全球市場:推動因素

第13章 推動因素的影響

第14章 痛風治療藥的全球市場:課題

第15章 推動因素與課題的影響

第16章 痛風治療藥的全球市場:趨勢

第17章 業者情勢

  • 競爭模式
  • 其他卓越供應商

第18章 主要供應商分析

  • AstraZeneca
  • Horizon Pharma
  • 武田藥品工業

第19章 附錄

  • 簡稱清單

第20章 關於Technavio

目錄
Product Code: IRTNTR10483

About Gout Therapeutics

Gout is one type of arthritis, which is caused by the high levels of uric acid in the blood. The main symptoms of gout are sudden attack of burning pain, swelling in a joint, and stiffness, usually in toe. If it is not treated, over time, it can harm tendons, joints, and other tissues. NSAIDs and urate-lowering agents are preferred treatment options for gout.

Technavio's analysts forecast the global gout therapeutics market to grow at a CAGR of 17.16% during the period 2016-2020.

Covered in this report

The report covers the present scenario and the growth prospects of the global gout therapeutics market for 2016-2020. To calculate the market size, the report considers the revenue generated from the sales of branded, generic, and off-label drugs used for the treatment of gout and the revenues to be generated from the sales of drugs that are expected to be launched into the market along with the decline in revenues from the patent expiries of the marketed drugs.

The market is divided into the following segments based on geography:

  • Americas
  • APAC
  • EMEA

Technavio's report, Global Gout Therapeutics Market 2016-2020, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the key vendors operating in this market.

Key vendors

  • AstraZeneca
  • Horizon Pharma
  • Takeda Pharmaceuticals

Other Prominent Vendors

  • Ablynx
  • Alder Biopharmaceuticals
  • Antares Pharma
  • Astellas Pharma
  • Boehringer Ingelheim
  • Can-Fite BioPharma
  • Celgene
  • Celltrion
  • ChemoCentryx
  • CymaBay Therapeutics
  • Eisai
  • Eli Lilly
  • Gilead Sciences
  • GlaxoSmithKline
  • Incyte
  • Ironwood Pharmaceuticals
  • JW Pharmaceutical
  • KaloBios Pharmaceuticals
  • Lexicon Pharmaceuticals
  • LG Life Sciences
  • Merck
  • Morphotek
  • Novartis
  • Novo Nordisk
  • Regeneron Pharmaceuticals
  • Sandoz
  • Sanofi
  • Santarus
  • Selecta Biosciences
  • Teijin Pharma
  • UCB
  • Vertex Pharmaceuticals.

Market driver

  • Introduction of novel urate-lowering agents
  • For a full, detailed list, view our report

Market challenge

  • Low physician and patient awareness
  • For a full, detailed list, view our report

Market trend

  • Focus on regenerative medicines
  • For a full, detailed list, view our report

Key questions answered in this report

  • What will the market size be in 2020 and what will the growth rate be?
  • What are the key market trends?
  • What is driving this market?
  • What are the challenges to market growth?
  • Who are the key vendors in this market space?
  • What are the market opportunities and threats faced by the key vendors?
  • What are the strengths and weaknesses of the key vendors?

You can request one free hour of our analyst's time when you purchase this market report. Details are provided within the report.

Table of Contents

PART 01: Executive summary

  • Highlights

PART 02: Scope of the report

  • Market overview
  • Top-vendor offerings

PART 03: Market research methodology

  • Research methodology
  • Economic indicators

PART 04: Introduction

  • Key market highlights

PART 05: Gout: Disease overview

PART 06: Pipeline portfolio

PART 07: Market landscape

  • Market overview
  • Five forces analysis

PART 08: Key buying criteria

PART 09: Market segmentation by drug class

  • NSAIDs
  • Corticosteroids
  • Colchicine
  • Urate-lowering agents

PART 10: Market segmentation by type of disease

PART 11: Geographical segmentation

  • Gout therapeutics market in Americas
  • Gout therapeutics market in EMEA
  • Gout therapeutics market in APAC
  • Market overview

PART 12: Market drivers

  • Introduction of novel urate-lowering agents
  • Technological advancements in medical imaging
  • Popularity of off-label and OTC drugs

PART 13: Impact of drivers

PART 14: Market challenges

  • Low physician and patient awareness
  • Heavy dependency on generic drugs
  • Use of CAM for treatment of gout

PART 15: Impact of drivers and challenges

PART 16: Market trends

  • Focus on regenerative medicines
  • High growth potential of biologics
  • Preference for combination therapies

PART 17: Vendor landscape

  • Competitive scenario
  • Other prominent vendors

PART 18: Key vendor analysis

  • AstraZeneca
  • Horizon Pharma
  • Takeda Pharmaceuticals

PART 19: Appendix

  • List of abbreviations

PART 20: Explore Technavio

List of Exhibits

  • Exhibit 01: Product offerings
  • Exhibit 02: Global gout therapeutics market overview
  • Exhibit 03: Stages of gout
  • Exhibit 04: Mechanism of gout
  • Exhibit 05: Gout: overview
  • Exhibit 06: Treatment algorithm for gout
  • Exhibit 07: Pipeline analysis of major companies for global gout therapeutics market
  • Exhibit 08: Share of pipeline molecules in global gout therapeutics market
  • Exhibit 09: Few pipeline candidates under development in global gout therapeutics market:
  • Exhibit 10: Market snapshot: Global gout therapeutics market
  • Exhibit 11: Global statistics for gout in 2015
  • Exhibit 12: Correlation between serum uric acid concentration and cigarette smoking status
  • Exhibit 13: Factors influencing the global gout therapeutics market 2015
  • Exhibit 14: Global gout therapeutics market snapshot: Developed and emerging markets 2015
  • Exhibit 15: Global gout therapeutics market 2015-2020 ($ billions)
  • Exhibit 16: Opportunities in gout arthritis industry today
  • Exhibit 17: Impact of drivers and challenges of global gout therapeutics market
  • Exhibit 18: Five forces analysis
  • Exhibit 19: Key buying criteria for gout therapeutics market
  • Exhibit 20: Key buying criteria for global gout therapeutics market 2015
  • Exhibit 21: Impact of key customer segments on global gout therapeutics market 2015
  • Exhibit 22: Market segmentation by drug class: Global gout therapeutics market
  • Exhibit 23: Common NSAIDs used for treatment of gout
  • Exhibit 24: Market segmentation by drug class: Present and future scenarios
  • Exhibit 25: Global gout therapeutics market: Segmentation by type 2015-2020
  • Exhibit 26: Global gout therapeutics market segmentation: Growth cycle analysis
  • Exhibit 27: Snapshot of global gout therapeutics market by segmentation
  • Exhibit 28: Snapshot of global gout therapeutics market by geography
  • Exhibit 29: Global gout therapeutics market revenue by geography 2015-2020 ($ millions)
  • Exhibit 30: Percentage share of global gout therapeutics market by geography 2015
  • Exhibit 31: Percentage share of global gout therapeutics market by geography 2020
  • Exhibit 32: Global gout therapeutics market: Country analysis based on revenue and growth rate
  • Exhibit 33: Gout therapeutics market in Americas 2015-2020 ($ millions)
  • Exhibit 34: Gout therapeutics market in EMEA 2015-2020 ($ millions)
  • Exhibit 35: Opportunity of RDEA3170 in APAC
  • Exhibit 36: Gout therapeutics market in APAC 2015-2020 ($ millions)
  • Exhibit 37: Phase III clinical study data and future opportunities for urate-lowering agent - Zurampic (lesinurad)
  • Exhibit 38: Impact of drivers
  • Exhibit 39: Common CAM therapies used for gout treatment
  • Exhibit 40: Usage of CAM therapies in US adults 2015
  • Exhibit 41: Impact of drivers and challenges
  • Exhibit 42: Impact of trends on global gout therapeutics market
  • Exhibit 43: Ranking of major vendors for global gout therapeutics market
  • Exhibit 44: Geographical presence of key vendors
  • Exhibit 45: Company portfolio analysis in global gout therapeutics market 2016-2020
  • Exhibit 46: AstraZeneca: Key highlights
  • Exhibit 47: AstraZeneca: Strength assessment
  • Exhibit 48: AstraZeneca: Strategy assessment
  • Exhibit 49: AstraZeneca: Opportunity assessment
  • Exhibit 50: Horizon Pharma: Key highlights
  • Exhibit 51: Horizon Pharma: Strength assessment
  • Exhibit 52: Horizon Pharma: Strategy assessment
  • Exhibit 53: Horizon Pharma: Opportunity assessment
  • Exhibit 54: Takeda Pharmaceuticals: Key highlights
  • Exhibit 55: Takeda Pharmaceuticals: Strength assessment
  • Exhibit 56: Takeda Pharmaceuticals: Strategy assessment
  • Exhibit 57: Takeda Pharmaceuticals: Opportunity assessment
Back to Top